 |
217 Diseases |  |
228 Trials |
|
228 Trials |  |
3892 News |  |
| «12...2324252627282930313233...4950» |
- | epirubicin / Generic mfg.
Journal: Carrying epirubicin on nanoemulsion containing algae and cinnamon oils augments its apoptotic and anti-invasion effects on human colon cancer cells. (Pubmed Central) - Jul 15, 2020
ALG-CN-EPI treatment suppressed the invasion ability of HCT116 cells to (32.98 ± 3.28)%, whereas the invasion ability of EPI exposed cells was only reduced to about (56 ± 1.81)%. In conclusion, the resulted new nanotherapeutics (ALG-CN-EPI) has potentiated the antitumor activity of EPI.
- | Trial completion date, Trial primary completion date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Jul 14, 2020
P2/3, N=60, Recruiting, Sponsor: Dr. Gordon Buduhan
In conclusion, the resulted new nanotherapeutics (ALG-CN-EPI) has potentiated the antitumor activity of EPI. Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Apr 2020 --> Jun 2021
- | metformin / Generic mfg.
Enrollment closed, Enrollment change: NeoMET Study in Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Jul 8, 2020
P2, N=92, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Apr 2020 --> Jun 2021 Recruiting --> Active, not recruiting | N=200 --> 92
- ||| Trial completion, Trial primary completion date, Real-world evidence, Real-world: Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. (clinicaltrials.gov) - Jul 8, 2020
P=N/A, N=1213, Completed, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Recruiting --> Active, not recruiting | N=200 --> 92 Not yet recruiting --> Completed | Trial primary completion date: Feb 2020 --> May 2020
- |||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) - Jul 7, 2020
P2, N=216, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Completed | Trial primary completion date: Feb 2020 --> May 2020 Not yet recruiting --> Recruiting
- | cytarabine / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Journal: Toxicity of cytarabine constant rate infusion in dogs with high-grade non-Hodgkin lymphoma with bone marrow or central nervous system involvement. (Pubmed Central) - Jul 4, 2020
Not yet recruiting --> Recruiting Our findings suggest that gastrointestinal toxicity should be expected in lymphoma patients undergoing cytarabine CRI.
- || fluorouracil / Generic mfg., Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
Clinical, Journal: The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids. (Pubmed Central) - Jul 3, 2020
Nab-paclitaxel showed strong anti-tumor activity and had the potential to become front-line drug for treating GC patients. Gastric cancer organoid may be a good tool to predict in vivo response to drugs.
- || doxorubicin liposomal / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Review, Journal: Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin. (Pubmed Central) - Jul 2, 2020
Gastric cancer organoid may be a good tool to predict in vivo response to drugs. Clinicians should pay attention to CIIP in breast cancer patients who receive more than three cycles of chemotherapy regimens containing pegylated liposomal doxorubicin plus cyclophosphamide with or without docetaxel.
- || doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Gp130 degradation induced by epirubicin contributes to chemotherapy efficacy. (Pubmed Central) - Jul 2, 2020
We also show that epirubicin-resistant tumor cells express higher level of gp130. Altogether, our results indicate that degradation of gp130 and subsequent reduction of gp130-Stat3 signaling contributes to epirubicin-induced tumor cell death.
- || epirubicin / Generic mfg.
Clinical, Journal: Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial. (Pubmed Central) - Jul 2, 2020
Following RNU, MIC did not change the natural course of BR beyond a single instillation apart from potentially delaying its occurrence. Lymphovascular invasion and blood transfusion were associated with worse BR and DSS outcomes, respectively.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC (clinicaltrials.gov) - Jul 2, 2020
P2, N=50, Active, not recruiting, Sponsor: Institut fuer Frauengesundheit
Lymphovascular invasion and blood transfusion were associated with worse BR and DSS outcomes, respectively. Trial primary completion date: May 2020 --> Sep 2020
- || vinorelbine tartrate / Generic mfg., Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre, epirubicin / Generic mfg.
Clinical, Journal, Combination therapy: Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. (Pubmed Central) - Jul 2, 2020
Oral VRL is comparable to IV VRL and an effective first-line treatment for Chinese patients with MBC. The activity of VRL + EPI combination is unaltered when VRL is given orally at recommended doses.
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Jun 30, 2020
P3, N=1846, Active, not recruiting, Sponsor: Hoffmann-La Roche
The activity of VRL + EPI combination is unaltered when VRL is given orally at recommended doses. Trial primary completion date: Jan 2024 --> Nov 2019
- || fluorouracil / Generic mfg., Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic mfg.
Clinical, Journal, Real-World Evidence: Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer. (Pubmed Central) - Jun 26, 2020
Survival rates of patients with HER2+ breast cancer in our study are comparable to those seen in clinical trials. Our findings support chemotherapy de-escalation in patients with node-negative disease and validate the efficacy of FEC-DH in those with node-positive disease.
- | fluorouracil / Generic mfg., Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic mfg.
Journal: Drug utilization and expenditure of anticancer drugs for breast cancer. (Pubmed Central) - Jun 23, 2020
The most commonly prescribed medication was fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen, which was used in 81% of patients...Docetaxel was the most commonly used drug in neoadjuvant setting, whereas letrozole and trastuzumab were prescribed more frequently in hormonal and targeted therapies, respectively...Our results indicated that adherence to a clinical guideline and recommended medication regimens improved patient outcomes. Our finding indicate how analyzing drug utilization pattern could benefit institutions in managing inventory and efficiently using health care resources.
- | chloroquine phosphate / Generic mfg., epirubicin / Generic mfg.
Journal: Chloroquine increases the anti-cancer activity of epirubicin in A549 lung cancer cells. (Pubmed Central) - Jun 23, 2020
The flow cytometry results demonstrated that the apoptosis rate was highest in the EPI + CQ group. In conclusion, the autophagy inhibitor CQ increased the sensitivity of A549 cells to EPI, and the underlying mechanism of action may be associated with the activation of apoptosis.
- | fluorouracil / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Journal: Cognitive impairment following chemotherapy for breast cancer: The impact of practice effect on results. (Pubmed Central) - Jun 20, 2020
In conclusion, the autophagy inhibitor CQ increased the sensitivity of A549 cells to EPI, and the underlying mechanism of action may be associated with the activation of apoptosis. Accounting for PE is recommended to identify true change on cognition through treatment with chemotherapy for breast cancer.
- | New P2 trial: Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy (clinicaltrials.gov) - Jun 18, 2020
P2, N=286, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Rituxan (rituximab) / Roche
New P2 trial: VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma (clinicaltrials.gov) - Jun 15, 2020
P2, N=60, Recruiting, Sponsor: Henan Cancer Hospital
- | Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic mfg., Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
Journal: NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. (Pubmed Central) - Jun 12, 2020
The significantly higher pathologic complete response rate with NAB-paclitaxel translated into a significantly improved iDFS in patients with early BC as compared with sb-paclitaxel. PSN improved much faster under NAB-paclitaxel 125 mg/m compared with NAB-paclitaxel 150 mg/m.
- || fluorouracil / Generic mfg.
Clinical, Journal: Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies. (Pubmed Central) - Jun 11, 2020
PSN improved much faster under NAB-paclitaxel 125 mg/m compared with NAB-paclitaxel 150 mg/m. HAIC with an FEM regimen is an effective salvage treatment for MBC patients with advanced LM.
- | epirubicin / Generic mfg.
Trial completion date, Trial primary completion date: Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus (clinicaltrials.gov) - Jun 11, 2020
P3, N=253, Recruiting, Sponsor: Shanghai Zhongshan Hospital
HAIC with an FEM regimen is an effective salvage treatment for MBC patients with advanced LM. Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Apr 2020 --> Oct 2020
- | sorafenib / Generic mfg.
Trial completion date, Surgery: Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 11, 2020
P2, N=20, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Apr 2020 --> Oct 2020 Trial completion date: Dec 2018 --> Dec 2020
- Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date, Tumor cell: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (clinicaltrials.gov) - Jun 11, 2020
P2, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Dec 2018 --> Dec 2020 Trial completion date: May 2020 --> Aug 2020 | Trial primary completion date: May 2020 --> Aug 2020
- || Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic mfg., Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer. (Pubmed Central) - Jun 10, 2020
Trial completion date: May 2020 --> Aug 2020 | Trial primary completion date: May 2020 --> Aug 2020 The two-weekly nab-P regimen is a good neoadjuvant chemotherapy choice for triple-negative breast cancer.
- | FDA event, Journal: Evaluation of a library of FDA-approved drugs for their ability to potentiate antibiotics against multidrug resistant Gram-negative pathogens. (Pubmed Central) - Jun 10, 2020
These ARB hits included antimetabolites (zidovudine, floxuridine, didanosine, gemcitabine), anthracyclines (daunorubicin, mitoxantrone, epirubicin) and psychoactive drugs (gabapentin, fluspirilene, oxethazaine). This suggests that there are few approved drugs which could be directly repositioned as adjunct-antibacterials and these will need robust testing to validate efficacy.
- ||| Clinical, P3 data, Journal: Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. (Pubmed Central) - Jun 10, 2020
This suggests that there are few approved drugs which could be directly repositioned as adjunct-antibacterials and these will need robust testing to validate efficacy. Achieving a pCR is important in HER2-positive disease and translates into better long-term outcome with regard to EFS and OS.
- || Decadron (dexamethasone) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
Clinical, Retrospective data, Journal: Mediastinal T lymphoblastic lymphoma/leukemia: clinicopathological and prognostic analyses of 61 cases (Pubmed Central) - Jun 7, 2020
The histological morphology is often difficult to interpret, while the addition of clinical features and immunohistochemistry may help. The combination of CKpan, TDT, CD99, CD7, CD3, PAX5, CD34, CD10, and Ki-67 immunohistochemicl studies may assist in diagnosis of the most cases.
- || Avastin (bevacizumab) / Roche
Biomarker, Clinical, Journal, Tumor microenvironment: Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER positive breast cancer. (Pubmed Central) - Jun 7, 2020
Improved treatment response was associated with higher proliferation rate and an immune phenotype characterized by high presence of classically activated M1 macrophages, activated NK cells and memory activated CD4 T-cells. Treatment with bevacizumab increased the number of adverse events, including hemorrhage, hypertension, infection and febrile neutropenia, but despite this, the ECOG status was not affected.
- || cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Early detection of cardiotoxicity by 3D speckle tracking imaging of area strain in breast cancer patients receiving chemotherapy. (Pubmed Central) - Jun 4, 2020
Interobserver consistency analysis showed that 3D-STI strain parameter measurement has good repeatability. GAS has greater value in predicting early myocardial damage after anthracycline chemotherapy.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P2 trial: NeoTENNIS: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Jun 4, 2020
P2, N=60, Recruiting, Sponsor: Fudan University
- ||| fluorouracil / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, P3 data, Journal: Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. (Pubmed Central) - Jun 4, 2020
Chemotherapy delays due to neutropenia and leukopenia were significantly decreased among patients that received G-CSF (OR 0.098, 95% CI 0.06-0.15 and OR 0.32, 95% CI 0.18-0.58, respectively). In conclusion, G-CSF support reduces neutropenic events and permits increased relative dose intensity, which is essential for improved survival outcomes.
- | fluorouracil / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Journal: Malignant adenomyoepithelioma of the breast. (Pubmed Central) - Jun 1, 2020
Malignant potency is related to the tumor size, tumor appearance, and mitoses, even if only a few. Given that ductal spread is one of the morphological features of malignant AME, it is of paramount importance to assess the surgical margins.
- || paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal, Tumor-Infiltrating Lymphocyte, PD(L)-1 Biomarker, IO Biomarker: Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. (Pubmed Central) - May 31, 2020
P3
TILs, PD-1 and PD-L1 are linked to each other indicating tumour immunogenicity. Moreover, PD-1-positive immune cells have a positive prognostic impact in TNBC.
- KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for HighRisk, Early-Stage, ER+/HER2− Breast Cancer () - May 29, 2020 - Abstract #ASBrS2020ASBrS_159;
P3
Dual primary endpoints are pCR rate (ypT0/Tis ypN0) and event-free survival (EFS). Secondary endpoints include ypT0/Tis and ypT0 ypN0 pCR rates in all patients and all 3 pCR definitions in those with PD-L1+ tumors, EFS in patients with PD-L1+ tumors, overall survival, safety, and health-related quality of life.
- || Clinical, Journal: UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup. (Pubmed Central) - May 29, 2020
This study did not show superiority of the concomitant anthracycline-taxane arm which was more toxic in high-risk node-positive breast cancer patients. Long-term results of the HER2-positive subpopulation are in line with those of the other adjuvant trastuzumab trials but quantitatively less pronounced mostly because of lack of power.
- | Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Metastases: B-IMMUNE: Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (clinicaltrials.gov) - May 28, 2020
P1/2, N=57, Recruiting, Sponsor: Grand H
Long-term results of the HER2-positive subpopulation are in line with those of the other adjuvant trastuzumab trials but quantitatively less pronounced mostly because of lack of power. Trial primary completion date: Apr 2020 --> Apr 2021
- ||||| TX05 (trastuzumab biosimilar) / Tanvex BioPharma
Enrollment closed: TX05-03: Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin (clinicaltrials.gov) - May 27, 2020
P3, N=809, Active, not recruiting, Sponsor: Tanvex BioPharma USA, Inc.
Trial primary completion date: Apr 2020 --> Apr 2021 Recruiting --> Active, not recruiting
- | doxorubicin hydrochloride / Generic mfg.
Journal: Cancer During Pregnancy: The Role of Vascular Toxicity in Chemotherapy-Induced Placental Toxicity. (Pubmed Central) - May 24, 2020
The immunohistochemistry of the EPI-treated human placentae showed enhanced proliferation and apoptosis as compared with matched chemo-naïve placentae, as well as reduced neovascularization (CD34). Our findings suggest that anthracycline-induced vascular insult promotes placental toxicity, and could point to potential agents designated to offset the damage and to reduce gestational complications in pregnant cancer patients.
- ||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) - May 22, 2020
P2, N=216, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | cyclophosphamide intravenous / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study. (Pubmed Central) - May 21, 2020
The incidence of FN in EC therapy among Japanese patients was higher than expected, EC therapy appears to be a high-risk chemotherapy for FN, and prophylactic administration of G-CSF is recommended. Maintaining high therapeutic intensity is associated with a positive prognosis for patients with early breast cancer, and prophylactic administration of G-CSF is likely to be beneficial in treatment involving EC therapy.
- | Trial completion, Enrollment change: Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy (clinicaltrials.gov) - May 19, 2020
P3, N=1570, Completed, Sponsor: Fudan University
Maintaining high therapeutic intensity is associated with a positive prognosis for patients with early breast cancer, and prophylactic administration of G-CSF is likely to be beneficial in treatment involving EC therapy. Active, not recruiting --> Completed | N=3200 --> 1570
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) - May 18, 2020
P2, N=12, Terminated, Sponsor: Shanghai Jiao Tong University School of Medicine
Active, not recruiting --> Completed | N=3200 --> 1570 N=258 --> 12 | Trial completion date: May 2028 --> Apr 2020 | Recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Apr 2020; We terminated this trial and initiated a new one including pertuzumab.
- || epirubicin / Generic mfg.
Clinical, Journal, Real-World Evidence: Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice. (Pubmed Central) - May 17, 2020
N=258 --> 12 | Trial completion date: May 2028 --> Apr 2020 | Recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Apr 2020; We terminated this trial and initiated a new one including pertuzumab. Our study showed the efficacy of IPIOC for the prevention of intravesical recurrence in primary intermediate-risk NMIBC patients regardless of BCG therapy.
- || doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. (Pubmed Central) - May 16, 2020
Our study indicates specific circulating miRNAs as possible prediction markers for cardiac troponin perturbation upon anthracycline treatment. Indeed, our findings hint at the possible future use of plasma miRNAs to predict the cardiac responsiveness of patients to different anticancer agents.
- | Journal: Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. (Pubmed Central) - May 16, 2020
This review will reveal the definitive clinical benefit CLDN18.2-targeting therapies have achieved and update the highlighting development (like chimeric antigen receptor T-cell immunotherapy) to CLDN18.2 positive patients. We then focus on 10 questions arisen from recent progress and anticipate to provide a future perspective for novel cancer treatment.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3146;
EGFR-targeted drug-free/EPI-encapsulated nano-TriNKEs were prepared by conjugating cetuximab (anti-EGFR), anti-4-BB, and anti-CD16 agonistic antibodies to PEG-PLGA NPs... Our data demonstrated that nano-TriNKEs are more effective in NK activation than free agonistic antibodies, and that the nanoengager platform provides more effective biological targeting, which is critical in NK-mediated cancer immunotherapy.
- doxorubicin hydrochloride / Generic mfg., irinotecan / Generic mfg.
Combining arsenic and topoisomerase inhibitors synergistically inhibit gastric cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2937;
Our research links arsenic compounds to the regulation of DNA damage repair and RAG1 expression as a mechanism for the cytotoxic effect. The combination of arsenic with topoisomerase inhibitors may represent a novel regimen for the treatment of gastric cancer and warrants further studies.
- doxorubicin hydrochloride / Generic mfg., irinotecan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Molecular profiling of ovarian cancer by targeted proteomics to inform personalized therapy (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2062;
Biomarkers of resistance include ERCC1 (Platinum), TUBB3 (taxanes), ALDH1A1 (cyclophosphamide) while response biomarkers include TOPO1 (irinotecan, topotecan), TOPO2A (doxorubicin, epirubicin), hENT1 (Gemcitabine).We also measure markers for several antibody-drug conjugates (FR-alpha, Her2, Trop2, gPNMB, MSLN)...Novel chemotherapy agents that could potentially be used include temozolomide (40% of patients did not express MGMT, resistance marker for temozolomide)...Others could potentially benefit from clinical trials targeting low Her2 expression. The ability to multiplex 72 protein biomarkers from 2-3 FFPE sections provides immense actionable information on clinical treatment or for patient stratification for clinical trials.
- paclitaxel / Generic mfg.
High-throughput screening and genome-wide analyses of 44 anticancerdrugs in the 1000 Genome cell lines reveals an association of the NQO1gene with the response of multiple anticancer drugs (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1675;
NQO1 has been previously shown to be a biomarker of epirubicin response, but our results reveal novel associations with these additional drug treatments. We interrogated the functional mechanisms of this association, demonstrating differences in both baseline and drug-exposed induction.